Literature DB >> 10729369

Effects of the cannabinoid receptor agonist, HU 210, on ingestive behaviour and body weight of rats.

D Giuliani1, A Ottani, F Ferrari.   

Abstract

The effect of the synthetic cannabinoid receptor agonist, (-)11-hydroxy-Delta(8)-tetrahydrocannabinol-dymethylheptyl (HU 210), on rat body weight and eating and drinking behaviour was examined. In Experiment 1, the drug (25, 50 or 100 microg/kg), sub-chronically administered for 4 days, produced a dose- and time-dependent loss of body weight that, at the highest dose, was not regained by 7 days after the drug was stopped, and remained markedly below that of vehicle-treated animals. In Experiment 2, food and water intakes, which were evaluated in fasted rats, tested as in Experiment 1, were significantly inhibited only by the dose of 100 microgram/kg, and this effect was still present 7 days after the last injection of the drug. The possibility that the effects observed are not directly dependent on the control of appetite and might be ascribable to stress-related phenomena is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729369     DOI: 10.1016/s0014-2999(00)00069-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

Review 1.  Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions.

Authors:  John D Salamone; Peter J McLaughlin; Kelly Sink; Alexandros Makriyannis; Linda A Parker
Journal:  Physiol Behav       Date:  2007-04-14

2.  Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice.

Authors:  D Song; R H J Bandsma; C Xiao; L Xi; W Shao; T Jin; G F Lewis
Journal:  Diabetologia       Date:  2011-02-22       Impact factor: 10.122

3.  The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats.

Authors:  P J McLaughlin; K M Winston; C L Limebeer; L A Parker; A Makriyannis; J D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2005-03-15       Impact factor: 4.530

4.  CB(1) cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction.

Authors:  Jens A Wagner; Kai Hu; Jan Karcher; Johann Bauersachs; Andreas Schäfer; Martin Laser; Hong Han; Georg Ertl
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

5.  Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice.

Authors:  Lei Wang; Jie Liu; Judith Harvey-White; Andreas Zimmer; George Kunos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

6.  Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test.

Authors:  Maria Flavia Barbano; Anna Castañé; Elena Martín-García; Rafael Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2009-05-19       Impact factor: 4.530

7.  Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054.

Authors:  Peter J McLaughlin; Ganesh A Thakur; V Kiran Vemuri; Evan D McClure; Cara M Brown; Keisha M Winston; Jodianne T Wood; Alexandros Makriyannis; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2013-04-19       Impact factor: 3.533

8.  HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat.

Authors:  Victoria S Dalton; Hongqin Wang; Katerina Zavitsanou
Journal:  Neurochem Res       Date:  2009-01-24       Impact factor: 3.996

9.  Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2.

Authors:  Elżbieta Radziszewska; Ewa Bojanowska
Journal:  Med Sci Monit Basic Res       Date:  2013-01-01

Review 10.  Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.

Authors:  Thomas Murphy; Bernard Le Foll
Journal:  Biomolecules       Date:  2020-06-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.